完成重组带状疱疹疫苗系列的克罗恩病患者接受Upadacitinib治疗后发生严重播散性带状疱疹病例

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY

ACG Case Reports Journal Pub Date : 2025-01-29 eCollection Date: 2025-02-01 DOI:10.14309/crj.0000000000001599

Nicole Lue, Lauren Burdine, Tamara Kahan, Kirthan Reddy, Ryan Nelson, Corina Lopez, Matthew Lee, Jacqueline Wolf

{"title":"完成重组带状疱疹疫苗系列的克罗恩病患者接受Upadacitinib治疗后发生严重播散性带状疱疹病例","authors":"Nicole Lue, Lauren Burdine, Tamara Kahan, Kirthan Reddy, Ryan Nelson, Corina Lopez, Matthew Lee, Jacqueline Wolf","doi":"10.14309/crj.0000000000001599","DOIUrl":null,"url":null,"abstract":"Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distribution. Disseminated HZ occurs when skin lesions erupt in numerous dermatomes. Upadacitinib is the first oral medication approved to treat moderate-severe Crohn's disease and has been associated with nonsevere cases of HZ. We present a case of a 60-year-old woman with refractory Crohn's disease who failed multiple immunosuppressive therapies, completed the recombinant zoster vaccines, and developed disseminated HZ on high-dose upadacitinib. She was treated with intravenous acyclovir, upadacitinib was discontinued, and was discharged on suppressive valacyclovir.","PeriodicalId":7394,"journal":{"name":"ACG Case Reports Journal","volume":"12 2","pages":"e01599"},"PeriodicalIF":0.6000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778084/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series.\",\"authors\":\"Nicole Lue, Lauren Burdine, Tamara Kahan, Kirthan Reddy, Ryan Nelson, Corina Lopez, Matthew Lee, Jacqueline Wolf\",\"doi\":\"10.14309/crj.0000000000001599\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distribution. Disseminated HZ occurs when skin lesions erupt in numerous dermatomes. Upadacitinib is the first oral medication approved to treat moderate-severe Crohn's disease and has been associated with nonsevere cases of HZ. We present a case of a 60-year-old woman with refractory Crohn's disease who failed multiple immunosuppressive therapies, completed the recombinant zoster vaccines, and developed disseminated HZ on high-dose upadacitinib. She was treated with intravenous acyclovir, upadacitinib was discontinued, and was discharged on suppressive valacyclovir.\",\"PeriodicalId\":7394,\"journal\":{\"name\":\"ACG Case Reports Journal\",\"volume\":\"12 2\",\"pages\":\"e01599\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11778084/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACG Case Reports Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/crj.0000000000001599\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACG Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/crj.0000000000001599","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

带状疱疹（HZ）是由水痘带状疱疹病毒的再激活引起的，在皮肤分布中表现为疼痛的水疱性病变。弥散性赫兹发作时，皮肤病变爆发在许多皮节。Upadacitinib是第一个被批准用于治疗中重度克罗恩病的口服药物，并与非严重的HZ病例相关。我们报告了一位60岁的难治性克罗恩病女性患者，她多次免疫抑制治疗失败，完成了重组带状疱疹疫苗的接种，并在大剂量upadacitinib的治疗下发展为弥散性HZ。她静脉注射阿昔洛韦，停用upadacitinib，出院时使用抑制性伐昔洛韦。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series.

Herpes zoster (HZ) is caused by the reactivation of the varicella zoster virus and presents with painful vesicular lesions in a dermatomal distribution. Disseminated HZ occurs when skin lesions erupt in numerous dermatomes. Upadacitinib is the first oral medication approved to treat moderate-severe Crohn's disease and has been associated with nonsevere cases of HZ. We present a case of a 60-year-old woman with refractory Crohn's disease who failed multiple immunosuppressive therapies, completed the recombinant zoster vaccines, and developed disseminated HZ on high-dose upadacitinib. She was treated with intravenous acyclovir, upadacitinib was discontinued, and was discharged on suppressive valacyclovir.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-

自引率

14.30%

发文量

170

审稿时长

12 weeks

期刊介绍： ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.